Neumora Therapeutics, Inc. (NMRA)

Market Cap	166.84M
Revenue (ttm)	n/a
Net Income (ttm)	-243.79M
Shares Out	161.98M
EPS (ttm)	-1.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	535,317
Open	1.090
Previous Close	1.100
Day's Range	1.020 - 1.125
52-Week Range	1.020 - 17.190
Beta	n/a
Analysts	Buy
Price Target	10.14 (+884.47%)
Earnings Date	Mar 3, 2025

About NMRA

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 15, 2023
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: NMRA
• Website: https://www.neumoratx.com

Analyst Forecast

According to 8 analysts, the average rating for NMRA stock is "Buy." The 12-month stock price forecast is $10.14, which is an increase of 884.47% from the latest price.

Price Target

$10.14

(884.47% upside)

Analyst Consensus: Buy